Article

BRAF Mutation Predicts a Poorer Clinical Prognosis for Papillary Thyroid Cancer

Department of Surgery, Johns Hopkins University, Baltimore, Maryland, United States
Journal of Clinical Endocrinology &amp Metabolism (Impact Factor: 6.31). 12/2005; 90(12):6373-9. DOI: 10.1210/jc.2005-0987
Source: PubMed

ABSTRACT Use of BRAF mutation in papillary thyroid cancer (PTC) has the potential to improve risk stratification of this cancer.
The objective of the study was to investigate the prognostic value of BRAF mutation in patients with PTC.
In a multicenter study of 219 PTC patients, data on their clinicopathological characteristics and clinical courses between 1990 and 2004 were retrospectively collected, and their tumor BRAF mutation status was determined. Associations of BRAF mutation with initial tumor characteristics and subsequent recurrence were analyzed.
Relationships between the BRAF mutation status and clinicopathological outcomes, including recurrence, were measured.
We found a significant association between BRAF mutation and extrathyroidal invasion (P < 0.001), lymph node metastasis (P < 0.001), and advanced tumor stage III/IV (P = 0.007) at initial surgery. This association remained significant on multivariate analysis, adjusting for conventional clinicopathological predictors of recurrence excluding the histological PTC subtype, but was lost when the tumor subtype was included in the model. BRAF mutation was also significantly associated with tumor recurrence, 25 vs. 9% with and without mutation, respectively (P = 0.004), during a median of 15 (interquartile range, 3-29) months of follow-up. This association remained significant on multivariate analysis adjusting for conventional clinicopathological predictors of recurrence, even including the PTC subtype (odds ratio, 4.0; 95% confidence interval, 1.1-14.1; P = 0.03). BRAF mutation was even an independent predictor of recurrence in patients with stage I/II disease, 22 vs. 5% with and without BRAF mutation, respectively (P = 0.002). BRAF mutation was also more frequently associated with absence of tumor I-131 avidity and treatment failure of recurrent disease.
In patients with PTC, BRAF mutation is associated with poorer clinicopathological outcomes and independently predicts recurrence. Therefore, BRAF mutation may be a useful molecular marker to assist in risk stratification for patients with PTC.

Download full-text

Full-text

Available from: Vasily V Vasko, Aug 31, 2015
0 Followers
 · 
285 Views
  • Source
    • "By inhibiting both cell surface tyrosine kinase receptors (e.g., vascular endothelial growth factor [VEGF] receptors) and intracellular serine/threonine kinases (e.g., BRAF), sorafenib produces antiproliferative and antiangiogenic effects [4]. Because differentiated thyroid cancers have been well documented to exhibit genetic alterations in the mitogen-activated protein kinase (MAPK) pathway, including BRAF mutations [5] and VEGF overexpression [6], sorafenib has been proposed as a good candidate therapy for refractory thyroid cancers. Recently, several reports have demonstrated substantial efficacy of sorafenib in the treatment of refractory thyroid cancers [2,7]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Distant metastases from papillary thyroid carcinoma (PTC) are rare and are associated with a poor prognosis. Here, we describe a patient with metastatic PTC who was treated with a tyrosine kinase inhibitor (TKI, sorafenib) for several months that was acutely exacerbated by discontinuation. A 43-year-old male was diagnosed with PTC in February 2004 and underwent total thyroidectomy followed by two courses of high-dose radioactive iodine (RAI) therapy. Despite two additional courses of high-dose RAI therapy, lung and muscle metastases were developed. Treatment with sorafenib was begun in September 2010. After 11 months treatment of sorafenib, newly developed metastatic lesions were found in mediastinal lymph nodes, liver, and bones. Considered as treatment failure, the administration of sorafenib was discontinued. Two weeks after sorafenib treatment was stopped, the disease progressed abruptly and caused death of the patient by respiratory failure. In our patient, PTC progressed rapidly after the cessation of sorafenib treatment. Patients with several other types of cancer have also experienced such rapid disease progression, termed "flare-ups." Physicians should be aware that flare-ups may occur in advanced PTC patients following the cessation of TKI therapy.
    09/2014; 29(3):388-93. DOI:10.3803/EnM.2014.29.3.388
  • Source
    • "In normal thyroid follicular cells, early BRAF V600E oncogene activation induces the expression of an miR-17-92 cluster [42]. The BRAF oncogene is the most frequent genetic alteration in thyroid cancer (i.e., PTC) and is also detected in ATC, associated with poor clinical-pathological features of cancer such as extrathyroidal invasion, short time recurrence, and distant metastases [43] [44]. High levels of miR-17-92 components are expressed in ATC [45], similar to that observed in other types of cancer, such as lung, colon, pancreatic, and lymphoma [46], especially in the aggressive forms of disease [47]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Anaplastic thyroid cancer (ATC) is among the most lethal types of cancers, characterized as a fast-growing and highly invasive thyroid tumor that is unresponsive to surgery and radioiodine, blunting therapeutic efficacy. Classically, genetic alterations in tumor suppressor TP53 are frequent, and cumulative alterations in different signaling pathways, such as MAPK and PI3K, are detected in ATC. Recently, deregulation in microRNAs (miRNAs), a class of small endogenous RNAs that regulate protein expression, has been implicated in tumorigenesis and cancer progression. Deregulation of miRNA expression is detected in thyroid cancer. Upregulation of miRNAs, such as miR-146b, miR-221, and miR-222, is observed in ATC and also in differentiated thyroid cancer (papillary and follicular), indicating that these miRNAs' overexpression is essential in maintaining tumorigenesis. However, specific miRNAs are downregulated in ATC, such as those of the miR-200 and miR-30 families, which are important negative regulators of cell migration, invasion, and epithelial-to-mesenchymal transition (EMT), processes that are overactivated in ATC. Therefore, molecular interference to restore the expression of tumor suppressor miRNAs, or to blunt overexpressed oncogenic miRNAs, is a promising therapeutic approach to ameliorate the treatment of ATC. In this review, we will explore the importance of miRNA deregulation for ATC cell biology.
    International Journal of Endocrinology 08/2014; 2014(743450):1-8. DOI:10.1155/2014/743450 · 1.52 Impact Factor
  • Source
    • "An analogous example is the successful stratification of different types of cancer, made possible by studying large groups of patients. The principle biomarkers for stratification are the morphology of cancer cells, genetic makeup of the cancer and particular proteins (Xing et al., 2005). In schizophrenia the successful stratification of the illness is likely to rely on biomarkers including genetics, neuroimaging and performance in neurocognitive tasks. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Early diagnosis and treatment of patients with psychosis is associated with improved outcome in terms of future functioning, symptoms and treatment response. Identifying neuroimaging biomarkers for illness onset and treatment response would lead to immediate clinical benefits. In this review we discuss if neuroimaging may be utilised to diagnose patients with psychosis, predict those who will develop the illness in those at high risk, and stratify patients. State-of-the-art developments in the field are critically examined including multicentre studies, longitudinal designs, multimodal imaging and machine learning as well as some of the challenges in utilizing future neuroimaging biomarkers in clinical trials. As many of these developments are already being applied in neuroimaging studies of Alzheimer's disease: we discuss what lessons have been learned from this field and how they may be applied to research in psychosis.
    European Neuropsychopharmacology 07/2014; 25(5). DOI:10.1016/j.euroneuro.2014.07.006 · 5.40 Impact Factor
Show more